ATRAID-dependent osteoclast responses
Cell-based study · Wild-type and Atraid-knockout RAW 264.7 cells differentiated into osteoclasts [1]
Alendronate-induced apoptosis and disruption of protein prenylation were attenuated by Atraid loss.
| Endpoint | Reported result | Reference |
|---|---|---|
| Annexin V-positive cells after 48 h | Qualitative response Atraid deficiency conferred resistance to alendronate-induced apoptosis. | [1] |
| Unprenylated Rap1a after 48 h | Qualitative response Atraid-knockout cells resisted alendronate-induced inhibition of prenylation. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- Annexin V assay: 0, 30 μM, 80 μM. Prenylation assay: 0, 20 μM, 80 μM.
- Exposure duration
- 48 hours
- Method
- Cell-culture exposure; wild-type and Atraid-knockout comparisons, including 0 μM controls.
- Reported limits
- Vehicle and exact salt/hydration not established in retrieved main text; supplementary methods and figure images not retrieved. Numerical response magnitudes not extracted.
Methods and source locations
Compound reported in the paper: Alendronate; Compound label in the paper: ALN
Alendronate active-moiety effects in the stated models; no hydrate-specific potency or mass-dose conversion.
Results, ATRAID is required cell-autonomously for N-BP inhibition of osteoclast function; Fig. 3E–F legend (BioC passages 24, 131)
Annexin V-positive cells after 48 h: Flow cytometry; 0, 30 μM, 80 μM alendronate; n=3 biological experiments; legend reports mean with standard deviation. — Results, ATRAID is required cell-autonomously for N-BP inhibition of osteoclast function; Fig. 3E–F legend (BioC passages 24, 131)
Unprenylated Rap1a after 48 h: Immunoblot; 0, 20 μM, 80 μM alendronate; Gapdh loading control. No band intensities estimated. — Results, ATRAID is required cell-autonomously for N-BP inhibition of osteoclast function; Fig. 3E–F legend (BioC passages 24, 131)